ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Propylene Glycol

Also written as “Propylene Glycol (0.6%)”, “Nanodrop®” and “Propylene Glycol, 0.6% eye drops”.

Its studies are mostly in Dry Eye Syndromes, led by 3 companies.

Drug pagePropylene Glycol: every studyAll 17 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Oct 18, 20133 company-led studies, 1 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Alcon10 open or runningno phasesince Oct 18, 2013Oct 18, 2013none ahead
Andover Research Eye Instituteits history only11 open or runningphase 4since Jun 24, 2026Jun 24, 2026none ahead
Laboratorios Sophia S.A de C.V.its history only10 open or runningphase 2since Sep 30, 2019Sep 30, 2019none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Alcon only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 18, 2013First study: no phase study in Dry Eye SyndromesFirst studyNCT01967147 · 279 enrolled

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

The one study Alcon leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT01967147Dry Eye Syndromes–CompletedJan 2015279

How it is read

Names in the registry

  • “Propylene Glycol (0.6%)”, 1 entry
  • “Nanodrop®”, 1 entry
  • “Propylene Glycol, 0.6% eye drops”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.